Literature DB >> 11447842

Neurofibrillary tangles and tau phosphorylation.

J P Brion1, B H Anderton, M Authelet, R Dayanandan, K Leroy, S Lovestone, J N Octave, L Pradier, N Touchet, G Tremp.   

Abstract

Neurofibrillary tangles (NFTs) are a characteristic neuropathological lesion of Alzheimer's disease (AD). They are composed of a highly-phosphorylated form of the microtubule-associated protein tau. We are investigating the relationship between NFTs and microtubule stability and how tau phosphorylation and function is affected in transgenic models and by co-expression with beta-amyloid precursor protein and presenilins. In most NFT-bearing neurons, we observed a strong reduction in acetylated alpha-tubulin immunoreactivity (a marker of stable microtubules) and a reduction of the in situ hybridization signal for tubulin mRNA. In transfected cells, mutated tau forms (corresponding to tau mutations identified in familial forms of frontotemporal dementias linked to chromosome 17) were less efficient in their ability to sustain microtubule growth. These observations are consistent with the hypothesis that destabilization of the microtubule network is an important mechanism of cell dysfunction in Alzheimer's disease. The glycogen synthase kinase-3 beta (GSK-3 beta) generates many phosphorylated sites on tau. We performed a neuroanatomical study of GSK-3 beta distribution showing that developmental evolution of GSK-3 beta compartmentalization in neurons paralleled that of phosphorylated tau. Studies on transfected cells and on cultured neurons showed that GSK-3 beta activity controls tau phosphorylation and tau functional interaction with microtubules. Tau phosphorylation was not affected in neurons overexpressing beta-amyloid precursor protein. Transgenic mice expressing a human tau isoform and double transgenic animals for tau and mutated presenilin 1 have been generated; a somatodendritic accumulation of phosphorylated transgenic tau proteins, as observed in the pretangle stage in AD, has been observed but NFTs were not found, suggesting that additional factors might be necessary to induce their formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447842     DOI: 10.1042/bss0670081

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  31 in total

1.  Stage-dependent BDNF serum concentrations in Alzheimer's disease.

Authors:  C Laske; E Stransky; T Leyhe; G W Eschweiler; A Wittorf; E Richartz; M Bartels; G Buchkremer; K Schott
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

2.  Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Authors:  Qiu-Lan Ma; Xiaohong Zuo; Fusheng Yang; Oliver J Ubeda; Dana J Gant; Mher Alaverdyan; Nicolae C Kiosea; Sean Nazari; Ping Ping Chen; Fatiha Nothias; Piu Chan; Edmond Teng; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

3.  Synthesis and Biological Evaluation of Novel Multi-target-Directed Benzazepines Against Excitotoxicity.

Authors:  Jatin Machhi; Navnit Prajapati; Ashutosh Tripathi; Zalak S Parikh; Ashish M Kanhed; Kirti Patel; Prakash P Pillai; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Neurobiol       Date:  2016-10-15       Impact factor: 5.590

4.  Inhibition of phosphorylation of JNK suppresses Aβ-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus.

Authors:  Parvin Yenki; Fariba Khodagholi; Fatemeh Shaerzadeh
Journal:  J Mol Neurosci       Date:  2012-06-17       Impact factor: 3.444

5.  Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury.

Authors:  Meenalakshmi M Mariappan; Sanjay Prasad; Kristin D'Silva; Esteban Cedillo; Kavithalakshmi Sataranatarajan; Jeffrey L Barnes; Goutam Ghosh Choudhury; Balakuntalam S Kasinath
Journal:  J Biol Chem       Date:  2014-10-22       Impact factor: 5.157

Review 6.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

7.  Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease.

Authors:  T Leyhe; Elke Stransky; G W Eschweiler; G Buchkremer; C Laske
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

8.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Association of GSK3B with Alzheimer disease and frontotemporal dementia.

Authors:  Barbara A J Schaffer; Lars Bertram; Bruce L Miller; Kristina Mullin; Sandra Weintraub; Nancy Johnson; Eileen H Bigio; Marsel Mesulam; Martina Wiedau-Pazos; George R Jackson; Jeffrey L Cummings; Rita M Cantor; Allan I Levey; Rudolph E Tanzi; Daniel H Geschwind
Journal:  Arch Neurol       Date:  2008-10

Review 10.  Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis.

Authors:  M Maulik; D Westaway; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.